详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Anesthesiology, Peking University People’s Hospital, Beijing 100044, China [2]Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China [3]Beijing Children’s Hospital, Capital Medical University, Beijing 100045, China [4]Department of Pharmacy, Peking University People’s Hospital, Beijing 100044, China

出处：

DOI：

ISSN：

关键词： population pharmacokinetics flurbiprofen postoperative pain weight height

摘要：

Background: Flurbiprofen axetil, a lipid-microsphere-carrier targeting preparation, is a nonsteroidal anti-inflammatory drug indicated for the treatment of postoperative pain. Aim: The aim of the study was to develop a population phamacokinetic (PPK) model of flurbiprofen, the active metabolite of flurbiprofen axetil, and optimize the treatment of flurbiprofen axetil in Chinese patients. Methods: A total of 144 therapeutic drug-monitoring samples of flurbiprofen axetil from 72 patients were included in this study. The pharmacologically active metabolite flurbiprofen was used as the analytical target and determined 5-45 minutes after intravenous administration. The PPK model for flurbiprofen was developed using Phoenix NLME 1.3 with a nonlinear mixed-effect model. Bootstrap and visual predictive checks were used simultaneously to validate the final PPK model. Potential covariates of age, sex, body weight, height, and body-mass index were tested for PK parameters. Results: The PPK model of flurbiprofen was explained by a one-compartment model with first-order elimination, in which a hypothetical-effect compartment was linked to a PK compartment. Population mean values of PK parameters estimated in the final model were theta(Ke) =0.0015/h, theta(Vd) =7.91 L, and theta(CL) =1.55 L/h. Analysis of covariates showed that height and weight influenced the K-e of flurbiprofen. The final model was proved to be robust. Conclusion: The final PPK model was demonstrated to be appropriate and effective, and can be used to assess the PK parameters of flurbiprofen in Chinese patients with postoperative pain.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 3 区医学

小类 | 3 区临床神经病学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区临床神经病学

JCR分区：

出版当年[2016]版：

Q2 CLINICAL NEUROLOGY

最新[2023]版：

Q2 CLINICAL NEUROLOGY

影响因子： 2.5 最新[2023版] 2.8 最新五年平均 2.581 出版当年[2016版] 0 出版当年五年平均 2.363 出版前一年[2015版] 2.645 出版后一年[2017版]

第一作者：

第一作者机构： [1]Department of Anesthesiology, Peking University People’s Hospital, Beijing 100044, China [2]Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Anesthesiology, Peking University People’s Hospital, Beijing 100044, China [*1]Department of Anesthesiology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Population pharmacokinetics of rotigotine extended-release microspheres for intramuscular injection in patients with early-stage Parkinson's disease [2]Population Pharmacokinetics of Vancomycin in Postoperative Neurosurgical Patients and the Application in Dosing Recommendation [3]群体药代动力学研究进展 [4]Population Pharmacokinetics of Sirolimus in Healthy Chinese Subjects [5]Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects (vol 9, 1316, 2018) [6]拉氧头孢钠在新生儿人群中群体药代动力学的分析研究 [7]Population Pharmacokinetics and Pharmacodynamics of Bivalirudin in Chinese Subjects [8]Population pharmacokinetics of lamotrigine in Chinese children with epilepsy [9]群体药代动力学在儿科临床药理学研究中的应用 [10]Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy